Shares of Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report) are set to reverse split on the morning of Monday, October 28th. The 1-10 reverse split was announced on Tuesday, October 15th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, October 25th.
Kazia Therapeutics Trading Down 1.5 %
NASDAQ:KZIA opened at $0.52 on Friday. Kazia Therapeutics has a 12 month low of $0.19 and a 12 month high of $1.58. The business’s 50-day moving average is $0.40 and its 200 day moving average is $0.36.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and set a $2.00 price objective on shares of Kazia Therapeutics in a research note on Friday, July 12th.
About Kazia Therapeutics
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
Featured Articles
- Five stocks we like better than Kazia Therapeutics
- What Makes a Stock a Good Dividend Stock?
- Texas Roadhouse Stock Steering for New Highs This Year
- What is an Earnings Surprise?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Read Stock Charts for Beginners
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
